Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clin...
Authors:
Jonathan W Wojtkowiak, Heather C Cornnell, Shingo Matsumoto, Keita Saito, Yoichi Takakusagi, Prasanta Dutta, Munju Kim, Xiaomeng Zhang, Rafael Leos, Kate M Bailey, Gary Martinez, Mark C Lloyd, Craig Weber, James B Mitchell, Ronald M Lynch, Amanda F Baker…
Citation:
Cancer & Metabolism
2015
3:2
Content type: Research
Published on: 29 January 2015